Table 2.
Correlations of pathway modules with outcome in breast cancer
| ER+ (n = 785) | ER- (n = 438) | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | Pval | HR | 95%CI | Pval | |
| MYC | 1.5 | 1.16-1.95 | 0.002 | 0.82 | 0.58-1.16 | 0.27 |
| E2F3 | 2.23 | 1.7-2.92 | < 10-8 | 0.71 | 0.5-1 | 0.05 |
| RAS | 1.38 | 1.06-1.79 | 0.02 | 1.13 | 0.8-1.59 | 0.5 |
| ERBB2 | 1.06 | 0.82-1.38 | 0.64 | 1.29 | 0.91-1.82 | 0.15 |
| EGFR | 0.93 | 0.72-1.21 | 0.59 | 1.82 | 1.28-2.59 | < 0.001 |
| AKT | 1.29 | 0.99-1.67 | 0.06 | 1.49 | 1.05-2.11 | 0.02 |
| IL12 | 0.88 | 0.68-1.15 | 0.35 | 0.52 | 0.36-0.74 | < 0.001 |
| IL4 | 0.96 | 0.74-1.25 | 0.77 | 0.93 | 0.66-1.31 | 0.69 |
| IL2 | 0.88 | 0.68-1.14 | 0.32 | 0.7 | 0.5-1 | 0.05 |
| IL13 | 1.28 | 0.98-1.66 | 0.07 | 1.29 | 0.91-1.82 | 0.15 |
| IFNG | 1.09 | 0.84-1.42 | 0.5 | 0.58 | 0.41-0.82 | 0.002 |
| TGFB | 0.93 | 0.71-1.2 | 0.57 | 1.65 | 1.16-2.34 | 0.004 |
For ER+ and ER- breast cancers in Set1 and for each pathway, we give the hazard ratio, 95%CI and the log-rank test P-value from a stratified Cox-proportional hazards regression model with cohorts as strata and with distant metastasis free survival (DMFS) as clinical endpoint. Pathway activation levels were divided into high/low activity levels according to values larger/lower than the median. Number of samples is given by n.